IL17A

(redirected from interleukin 17A)

IL17A

A gene on chromosome 6p12 that encodes interleukin-17A, a proinflammatory cytokine produced by activated T cells which regulates NF-kappaB and mitogen-activated protein kinases. It upregulates IL6 and cyclooxygenase-2 and increases nitric oxide production.

Molecular pathology
IL17A is overexpressed in rheumatoid arthritis, psoriasis and multiple sclerosis.
References in periodicals archive ?
According to the company, Taltz (ixekizumab) is a monoclonal antibody that selectively binds with interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor.
Taltz (ixekizumab) is a monoclonal antibody that selectively binds with interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor.1 IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses.
Lilly said Tuesday ahead of the market open that Talz, a monoclonal antibody that selectively binds with interleukin 17A (IL-17A) cytokine, met the primary and all major secondary endpoints up to 12 weeks in the Phase 4 IXORA-R study.
Here we report a second case of GA developing in a patient treated with the interleukin 17A antagonist secukinumab.
Glabinski, "Interleukin 17A promotes lymphocytes adhesion and induces CCL2 and CXCL1 release from brain endothelial cells," International Journal of Molecular Sciences, vol.
Booth et al., "A protective function for interleukin 17A in T cell-mediated intestinal inflammation," Nature Immunology, vol.
Interleukin 17A:Toward a new understanding of psoriasis pathogenesis.
Hollis-moffatt et al., "Association analysis of the interleukin 17A gene in Caucasian rheumatoid arthritis patients from Norway and New Zealand," Rheumatology, vol.
That rate dropped precipitously and in dose-dependent fashion in response to subcutaneous therapy with ixekizumab, a super-potent psoriasis medication directed against interleukin 17A, according to Dr.
The culprit, found in research on mice with asthma-like symptoms, is an immune system molecule called interleukin 17A (IL-17A).
The culprit, found in research on mice with asthma-like symptoms, is an immune system signalling molecule called interleukin 17A (IL-17A).
According to the company, TALTZ is a humanized IgG4 monoclonal antibody that selectively binds with the interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor.